REGN

Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
$755.51
+9.05 (+1.21%)
Mkt Cap: 78.50B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield5.1%
Dividend YieldN/A
Market Cap78.50B
Volume637.7K
Recent News
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
zacks.com · 2026-04-14
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
zacks.com · 2026-04-13
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com · 2026-04-13
Telix and Regeneron Announce Strategic Radiopharma Collaboration
globenewswire.com · 2026-04-13
Regeneron and Telix Announce Strategic Radiopharma Collaboration
globenewswire.com · 2026-04-13
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
globenewswire.com · 2026-04-13

Unlock the Full Deep Scan

9 AI agents analyze REGN across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →